Who should not take peptides: what the record shows

Who should not take peptides?

review

No one list answers this, because peptides are not one thing with one set of warnings. An approved medicine comes with a label that names the people it should not be given to, and that label was written from trials. An unapproved research compound has no label at all, so the only guide is who its studies enrolled and what went wrong in them. A 2026 review of injectable peptides in sports medicine draws the line plainly: for joint and muscle use, semaglutide and its class are the only peptides with reproducible randomized evidence behind them, in that case for knee osteoarthritis1. Compounds such as BPC-157, the thymosins and the growth hormone releasers remain investigational, with uncertain safety profiles1. The same authors write that clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols1. That is advice to doctors rather than a rule anyone enforces. The groups below are the ones the record actually has something to say about.

Who did the trials leave out, and why does that matter?

human RCT

Most peptide trials were built around one illness in one age group, and everyone else stayed outside the door. A 2026 review of peptide use in sport and bodybuilding notes that most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding2, where supraphysiological means above the levels the body makes on its own. The same review says the extent of peptide use in the general population is unknown2, so the people buying these compounds have not even been counted, let alone followed. The trials that do exist are narrow in a second way: one MK-677 trial took 65 healthy adults aged 60 to 813, and another enrolled 123 elderly hip fracture patients4. A result in one of those groups describes that group, and not studied in a group does not mean safe in that group, any more than it means harmful. It means the studies behind this page did not ask, which is a reason for care rather than comfort.

Who should not take peptides for weight loss?

human RCT

The approved weight-loss peptides are the one place where a regulator has written the answer down, product by product. Those labels and their warnings are taken apart on the Semaglutide safety page, the Tirzepatide safety page and the Liraglutide safety page, including whether the drugs raise the risk of pancreatitis or thyroid cancer. What the research behind this page adds is who the trials were run in. The semaglutide trial in teenagers randomised 201 young people5, and all but one of the participants had obesity5. A liraglutide trial in younger children opened by noting that, when it was written, no medicine was approved for common obesity in children younger than 12 years of age6. The youth diabetes trial of the same medicine found its benefit came at the cost of an increased frequency of gastrointestinal adverse events7. None of those groups is a person of ordinary weight hoping to lose a few kilograms. The unapproved fat-loss peptides carry no label at all. AOD-9604 is reported to mimic the lipolytic properties of growth hormone without the diabetogenic side effects8, meaning fat breakdown without the rise in blood sugar, but the paper repeating that claim was a drug-testing study rather than a test of it.

What peptides should be avoided with cancer?

human RCT

The concern in the record attaches to one family: compounds that raise growth hormone or IGF-1, the growth factor the liver makes when growth hormone tells it to. That family takes in growth hormone itself, MK-677, CJC-1295, sermorelin and recombinant IGF-1. The plainest statement comes from a 2009 review of recombinant IGF-1, which says the anti-apoptotic properties of IGF-I are implicated in cancer pathogenesis9, and calls that a concern for long-term therapy, anti-apoptotic meaning that it helps cells dodge the built-in death that normally clears out damaged ones. The releasing compounds act further up the same chain, and a 1998 review records that prolonged, intermittent oral administration increases insulin-like growth factor I (IGF-I) levels10, and in a two-year trial daily MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults3. The largest record, a registry of 83 803 treated children11, lists neoplasm and cancer among its most common serious events11, with no untreated group beside them for comparison. None of the studies behind this page enrolled people with an active cancer and watched the tumour, so the warning rests on what IGF-1 does to cells rather than on a trial in patients. Each compound's own record on this is on the HGH safety page, the IGF-1 safety page and the MK-677 safety page.

Is there a cancer question for the healing peptides?

systematic review

Less is on record, which is not the same as less reason to ask. BPC-157 is mostly sold for tendon and muscle repair, and a 2025 systematic review reports that it enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis12, the growth of new blood vessels, which are processes a tumour also depends on. Yet none of the studies covered here gave BPC-157 to anyone with cancer, and the same review reports that no clinical safety data were found12 at all, so the question is open in both directions. Epitalon has the opposite kind of record, all of it in animals: in mice bred to develop breast tumours, the peptide decreased the incidence of breast adenocarcinomas13, while in a rat bladder-tumour model no inhibitory effect of Epitalon was recorded14. Results in bred mice say nothing about a person with a diagnosis. Anyone asking which peptide kills cancer cells will meet PNC-27, which in a lab study was cytotoxic to human primary cancer cells that had been freshly isolated from two ovarian epithelial cancers15. That is a result in a dish, with no treated patients among these sources, and it is not a treatment.

Can you take peptides while pregnant?

animal model

Among the research behind this page, no trial gave a peptide to pregnant women to find out whether it harmed them or the baby. What exists is animal work and the body's own pregnancy hormones. In pregnant mice, thymosin beta-4, the natural protein behind TB-500, was injected twice late in gestation, and the pups showed more advanced development of lungs, heart, kidney, cerebral cortex and notochord16. In a mouse model of diabetes during pregnancy, MOTS-c improved blood sugar and reduced birth weight and the death of offspring17 caused by the disease. Both are effects on a growing fetus, and an effect in either direction is the reason a pregnancy needs its own trial rather than a guess borrowed from adults. Some peptides are pregnancy hormones in their own right. The placenta releases high levels of kisspeptin into the maternal circulation18, where it plays a physiological role in the islet adaptation to pregnancy18, meaning it helps the insulin-making cells keep up. hCG is the other reproductive hormone in this group, and both records are read on the HCG safety page and the Kisspeptin safety page.

What is known about peptides while breastfeeding?

review

Very little is known, and nearly all of it concerns one hormone: for growth hormone, the standard lactation reference says the limited data show that no adverse effects are experienced by the breastfed infants of mothers who receive somatropin19. The word limited is doing real work in that sentence, and one maker's caution is about the liquid used to mix the powder rather than the hormone itself: the manufacturer of Zomacton 5 mg recommends avoiding the use of the diluent, which contains benzyl alcohol, for lactating women19. That is a useful reminder that a vial holds more than its peptide. For the research compounds sold online, none of the sources covered here measured how much reaches breast milk, so for them the question is simply open. The fuller growth hormone entry, including the newer weekly versions, sits on the HGH safety page.

Are peptides safe for children?

human RCT

Children are, oddly, where several peptides have their firmest trial record, because growth hormone and IGF-1 were developed as medicines for children. Lonapegsomatropin, a once-weekly form of growth hormone, received its first approval in August 2021 in the USA20 for children at least a year old whose own growth hormone falls short. Recombinant IGF-1, sold as mecasermin, is approved in the US for long-term use in children with growth failure and severe primary IGF-I deficiency21. The weight-loss peptides have followed the same path, with liraglutide tested in children aged 6 to under 126 and tirzepatide in youth-onset type 2 diabetes22. Every one of those records belongs to a child with a diagnosis, given an approved product and watched by a specialist. None of it speaks to a teenager buying a research vial. That second group is real, and a 2026 review describes it only through anecdotal reports of growing uptake among recreational gym-goers, including younger individuals2.

What has gone wrong in children given growth-promoting peptides?

review

The clearest signal in children is early puberty, and a 2025 analysis of the FDA's adverse event reports found 529 reports of drug-induced early puberty23, and somatropin turned up in 52 of them, behind only testosterone23. Mecasermin, the IGF-1 drug, had one of the strongest signals, with a reporting odds ratio of 145.4223, a measure of how much more often a drug appears in these reports than chance would predict. Reports like these can raise a question but cannot settle one, since anyone may file them and the children who were fine are never counted. For IGF-1 itself, the 2009 review names hypoglycemia as the most frequent side effect9, which is blood sugar falling too low, and it also lists hyperplasia of lymphoid tissue, which may require tonsillectomy/adenoidectomy9, meaning the tonsils and adenoids can swell enough to need removal. For sermorelin, a short copy of the body's growth hormone releasing signal, the events reported most often in children were transient facial flushing and pain at injection site24.

What does anti-doping status mean for athletes?

systematic review

For a competing athlete the question has a second answer that has nothing to do with health. Sport prohibits whole families of peptides, and a 2023 testing paper states that the use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA)25. Another testing paper names sermorelin, tesamorelin and CJC-1295 as members of that family26. AOD-9604 is banned by the World Anti-doping Agency (WADA)8 as a possible performance enhancer, and a 2022 paper on blood testing notes that the yearly list names more and more of these peptides27. BPC-157 shows how unsettled the edges can be, since one 2025 review describes its use being banned in professional sports12, while another records that it is not currently listed as banned by the WADA28. The second risk is a product holding something other than its label. Among 60 supplements bought from vendors in 202029, MK-677 and YK-11, not disclosed on the label, were detected in some products29, so an athlete can fail a test on an ingredient nobody told them about. Whether a test would find a given peptide is taken up on the safety overview.

What about people with heart disease or high blood pressure?

human RCT

The clearest heart signal in this record comes from MK-677, not from the peptide most people link with blood pressure, since a 2011 trial gave MK-677 to elderly people recovering from a hip fracture, and the trial was terminated early due to a safety signal of congestive heart failure in a limited number of patients4. Its authors concluded that the compound has an unfavorable safety profile in this patient population4. That is one group of frail, older patients, and it does not tell anyone what the same compound does to a fit adult of thirty, though it is the group most like someone who already has a weak heart, and the full trial is read on the MK-677 safety page. Across bodybuilding use more widely, a 2026 review lists emerging risks of cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability2, the third of those meaning abnormal blood fats. For PT-141, the approved libido drug, the blood pressure question has a trial record of its own, set out on the PT-141 safety page.

What about people with diabetes?

human RCT

Two separate problems sit here, and the first is the growth-promoting compounds, which can move blood sugar in either direction. Recombinant IGF-1 pushes it down9, and the 2009 review notes that although the insulin-sensitizing effect may benefit both type 1 and type 2 diabetes, there are no ongoing clinical trials because of concern about risk of retinopathy and other complications9. Retinopathy is damage to the back of the eye, a part of the body that diabetes already threatens on its own. The releasing compounds have a shorter record on this than a reader might hope. In 18 children given MK-677 for about a week30, there was no change in serum glucose or insulin30, which is days of data rather than a verdict; the longer adult record is on the MK-677 safety page. The second problem is the weight-loss drugs, which were tested in people with diabetes on purpose, and in the youth liraglutide trial all the patients received metformin during the trial7, so the record already includes people on another sugar-lowering medicine. What happens when a research compound is added to that mix is not covered by any of the studies behind this page.

What about older adults, or people with kidney or liver disease?

systematic review

Older adults have more trial data than most groups, largely because of MK-677. Its two-year trial in healthy people aged 60 to 81 ran without serious adverse effects3, though the authors write that study power (duration and participant number) was insufficient to evaluate functional end points3. The heart failure signal in frail hip fracture patients sits beside that result, and the pair shows how much the health of the person changes the answer. Allergic reactions belong here too, and a 2024 case report describes a fulminant anaphylactic reaction, a sudden and severe allergic collapse, in an 85-year-old man given cerebrolysin after a stroke31, noting that only rare cases of anaphylaxis due to cerebrolysin have been published31. For the kidneys and liver the record is thinner still, and a 2025 review states that BPC-157 is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys12. That says which organs handle it, not what happens when those organs are failing, and none of the studies covered here enrolled people with kidney or liver disease to find out.

What should be avoided when taking peptides?

systematic review

On the record, most of the avoidable risk lives in the vial rather than in the molecule. A 2026 review of peptide use in sport says the largely unregulated supply chain exacerbates these dangers, as products are often mislabeled or contaminated2. The 2025 BPC-157 review lists the same causes, writing that adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety12. Stacking several compounds at once is the other theme that keeps coming back, because combined protocols are, by that first review's account, not what most published trials examined. What should not be mixed into a vial, and how one is kept, is covered on the handling and storage overview.

Where are the answers for a single compound?

Most people asking who should not take a peptide have one particular peptide in mind, and the answer for each sits on that compound's own safety page, built from its own trials and its own exclusions. The questions asked most often concern retatrutide, read on the Retatrutide safety page, followed by PT-141 and Semax, which have their own records at the PT-141 safety page and the Semax safety page. Collagen is handled at the Collagen safety page, and the smaller compounds are covered at the MOTS-c safety page, the KPV safety page, the Thymosin Alpha-1 safety page, the NAD+ safety page and the Glutathione safety page. Each of those pages carries a section on who its studies left out, which is the narrow version of the question this page asks across the whole category. Every documented harm, compound by compound, is gathered together at the safety overview.